LRG Webcast: Symptom and Side Effect Management (Hebrew Subtitles)
Originally published in June of 2019, GIST Israel provided Hebrew subtitles for this webcast on Symptom & Side Effect Management.
Originally published in June of 2019, GIST Israel provided Hebrew subtitles for this webcast on Symptom & Side Effect Management.
Symptom and Side Effect Management of GIST Treatment GIST and its treatment can cause a variety of symptoms. Adequate management of symptoms can improve a patient’s quality of life. Proper management can also allow [...]
What Can SideEQ Do for You? What is personalized side effect management, and why is it important for your survival and quality of life? “Never judge a person until you’ve walked a mile in [...]
"Summer, Summer almost here. Let’s give summer a big fat cheer! Of this fact, I’m surely clear: summer is the best time of year." ~Tim Rasinski Many people love the warm sun, [...]
The Life Raft Group is pleased to announce a new collaboration to provide access to our valuable resource tool, SideEQ, to the LeioMyoSarcoma Patient-Family-Care Partner Community. Commencing on May 5, members of [...]
Until cures are found, drug therapies are a lifeline to someone with cancer. Yet, the Life Raft Group’s GIST Patient Registry has recorded over 800 reports of patients interrupting their drug therapy usage because [...]
We are in the midst of one of the most exciting times in history to be involved in cancer research. Over 60 anti-cancer drugs have gained FDA-approval in the last 10 years, and that [...]
In a recent article in Cure Today, LRG Marketing Director, Erin Kristoff, details the importance of side effects management and the role the LRG plays in helping to extend survival and to improve the [...]
The heart is at the center of the cardiovascular system, the main function of which is to pump blood throughout the body, providing tissue and organs with the oxygen and nutrients they need. To [...]
A recent comprehensive review of the literature of the PubMed database and of the clinical experiences of oncologists and dermatologists concerning patients with regorafenib (Stivarga) related hand-foot skin reaction (HFSR) was published in the [...]